Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16522821rdf:typepubmed:Citationlld:pubmed
pubmed-article:16522821lifeskim:mentionsumls-concept:C0024305lld:lifeskim
pubmed-article:16522821lifeskim:mentionsumls-concept:C0038951lld:lifeskim
pubmed-article:16522821lifeskim:mentionsumls-concept:C1705576lld:lifeskim
pubmed-article:16522821lifeskim:mentionsumls-concept:C0022341lld:lifeskim
pubmed-article:16522821pubmed:issue1lld:pubmed
pubmed-article:16522821pubmed:dateCreated2006-6-22lld:pubmed
pubmed-article:16522821pubmed:abstractTextWe retrospectively surveyed the data of 233 patients who underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-HSCT) for non-Hodgkin lymphoma (NHL). Donors were HLA-matched relatives in 154 patients (66%) or unrelated volunteers in 60 (26%). Ninety patients (39%) were in complete remission. One hundred ninety-three (83%) received a total body irradiation (TBI)-based regimen, and 40 (17%) received a non-TBI-based regimen. Acute graft-versus-host disease (GVHD) occurred in 155 (67%) of the 233 evaluable patients; grade II to IV in 90 (39%), and grade III to IV in 37 (16%). Treatment-related mortality (TRM) was observed in 98 patients (42%), and 68% of them were related to GVHD. In a multivariate analysis, chemoresistance, prior autograft, and chronic GVHD were identified as adverse prognostic factors for TRM. Relapse or progression of lymphoma was observed in 21%. The 2-year overall survival rates of the patients with indolent (n = 38), aggressive (n = 111), and lymphoblastic lymphoma (n = 84) were 57%, 42%, and 41%, respectively. In a multivariate analysis, chemoresistance, prior autograft, and prior radiotherapy were identified as adverse prognostic factors for overall survival. Although myeloablative allo-HSCT represents an effective therapeutic option for patients with NHL, more work is still needed to decrease TRM and relapse.lld:pubmed
pubmed-article:16522821pubmed:languageenglld:pubmed
pubmed-article:16522821pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16522821pubmed:citationSubsetAIMlld:pubmed
pubmed-article:16522821pubmed:statusMEDLINElld:pubmed
pubmed-article:16522821pubmed:monthJullld:pubmed
pubmed-article:16522821pubmed:issn0006-4971lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:HaradaMineMlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:HottaTomomits...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TanakaYujiYlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TobinaiKensei...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TakaueYoichiYlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:KamiMasahiroMlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TanosakiRyuji...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:UchidaToshiki...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:IchinoheTatsu...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:SaoHiroshiHlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TakeuchiKengo...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:IzutsuKojiKlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:IshikawaTakay...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TaniguchiShui...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:KasaiMasaharu...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:HiguchiMasaka...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:KimSung-WonSWlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:KishiKenjiKlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:MoriShin-Ichi...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:FukudaTakahir...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:HirabayashiNo...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:KasaiMasanobu...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:KohnoAkioAlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:GotoSeiichiSlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:YoshiokaSatos...lld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TajimaKinukoKlld:pubmed
pubmed-article:16522821pubmed:authorpubmed-author:TanimotoTetsu...lld:pubmed
pubmed-article:16522821pubmed:issnTypePrintlld:pubmed
pubmed-article:16522821pubmed:day1lld:pubmed
pubmed-article:16522821pubmed:volume108lld:pubmed
pubmed-article:16522821pubmed:ownerNLMlld:pubmed
pubmed-article:16522821pubmed:authorsCompleteYlld:pubmed
pubmed-article:16522821pubmed:pagination382-9lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:meshHeadingpubmed-meshheading:16522821...lld:pubmed
pubmed-article:16522821pubmed:year2006lld:pubmed
pubmed-article:16522821pubmed:articleTitleMyeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan.lld:pubmed
pubmed-article:16522821pubmed:affiliationHematology and Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.lld:pubmed
pubmed-article:16522821pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16522821pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16522821lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16522821lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16522821lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16522821lld:pubmed